Psychiatry Practice EBITDA Multiples 2026: Real Ranges

Psychiatry Practices

Psychiatry Practice EBITDA Multiples in 2026: What Practices Are Really Selling For

If you're a psychiatry practice owner exploring a sale, the first number you'll hear from buyers, brokers, and well-meaning colleagues is a multiple. "Psychiatry is going for 6x." "I heard a guy got 9x." "Solo practices only do 3x." Every one of those statements is partially true and dangerously incomplete.

Psychiatry practice EBITDA multiples in 2026 don't live in a single number — they live in a range, and where your practice lands inside that range is determined by very specific, very controllable factors. A solo psychiatry practice with messy books and a retiring owner can transact at a low single-digit multiple in the same quarter that a multi-provider psychiatry group with a strong telepsychiatry book and clean QoE prints a double-digit multiple to a private equity-backed platform.

This guide gives you the real ranges psychiatry practices are transacting at right now, broken down by practice profile, the four levers that move you up or down inside the range, and the specific buyer behaviors driving 2026 multiple expansion (and the specific risks pulling certain deals lower). Everything here is grounded in real psychiatry deal flow — not generic healthcare averages.

Tony Siebel — Founder & Managing Director, Olympic M&A

Top 50 M&A Advisors 2025 · $70M+ in completed healthcare M&A transactions · 60+ published articles on healthcare consolidation · Specialized advisor for psychiatry practice sellers

What "EBITDA Multiple" Actually Means in a Psychiatry Practice Sale

Before we get to the numbers, the math has to be precise — because every dollar of imprecision compounds.

EBITDA is earnings before interest, taxes, depreciation, and amortization. In a psychiatry practice context, the version that matters is adjusted (or "normalized") EBITDA — your reported earnings, reset to reflect what the practice will produce under new ownership.

That reset typically includes:

Adding back owner compensation above fair-market clinical pay
Adding back personal expenses run through the practice
Adding back one-time legal, real estate, or build-out costs
Subtracting the cost of replacing the selling psychiatrist's clinical work at market rate (if they're stepping back at close)
Normalizing rent if the seller owns the real estate and charges below- or above-market rent

The multiple is what a buyer will pay for each dollar of that adjusted EBITDA. Enterprise value = Adjusted EBITDA × Multiple.

A practice with $600K of adjusted EBITDA at a 7x multiple is worth $4.2M of enterprise value. The same $600K at a 4x multiple is $2.4M. The same dollar of earnings — and a $1.8M difference at closing — based entirely on where you land inside the multiple range.

LEARN MORE — Psychiatry Practice Valuation: What Drives Value in 2026

A deeper walkthrough of how the EBITDA number itself gets built.

Psychiatry Practice EBITDA Multiples in 2026 — The Real Ranges

The multiples below reflect the actual range of psychiatry practice transactions in the current market. They are not asking-price multiples and they are not theoretical. They are what real buyers — solo strategic acquirers, regional psychiatry consolidators, and private equity-backed platforms like LifeStance, Mindpath Health, Talkiatry, and ARC Health — are actually paying.

Solo Psychiatry Practice (1 Provider)

Typical multiple range: 5.0x – 6.6x adjusted EBITDA

A solo psychiatry practice is, to most institutional buyers, a personal services business. The cash flow is tied to the owner's chair. When the owner leaves, the risk that patients leave with them — or that the practice can't be staffed at the same productivity — is real and underwritten directly into the offer.

Solo practices that price at the upper end of this range typically have:

A credible transition plan (the owner stays 12–24 months, or a successor is already in place)
A strong cash-pay or out-of-network book with documented multi-year stability
A TMS suite or Spravato program adding non-replicable revenue
Clean financials with a documented add-back schedule

Solo practices at the lower end are usually owner-retiring-at-close, in-network only, with no service-line differentiation and reconstructed financials.

LEARN MORE — Preparing Your Psychiatry Practice for Sale

If you’re solo and want to move from the low end of the range to the high end, this is the work.

Small Group Psychiatry Practice (2–4 Providers)

Typical multiple range: 5.5x – 7.0x adjusted EBITDA

Once you cross from solo to a real group — meaning at least one additional psychiatrist or psychiatric nurse practitioner producing an independent panel — the multiple structurally lifts. You're no longer selling a personal services business; you're selling a small clinical organization with provider redundancy and reduced founder concentration risk.

Small groups at the upper end typically have:

No single provider above 40% of revenue
30%+ telepsychiatry mix
Documented contracted payer rates with the major commercial plans
Three years of growing or stable EBITDA
A clean QoE-ready financial package

Small groups at the lower end usually have a dominant founding psychiatrist (60%+ of revenue), heavy in-network commercial concentration with one payer, and no service-line differentiation.

Mid-Size Psychiatry Group (5–10 Providers)

Typical multiple range: 6.0x – 8.0x adjusted EBITDA

This is the band where institutional psychiatry buyers compete most aggressively. A 5–10 provider group with $1.5M–$4M of adjusted EBITDA, multi-state telepsychiatry capability, and a real management layer below the founding psychiatrist is exactly what platform consolidators are built to acquire.

Mid-size groups at the upper end of the range almost always feature:

A management layer (clinical director, practice manager, billing lead)
30–50% telepsychiatry mix
Multi-state licensure for a meaningful share of providers
TMS, Spravato, or both, scaled to material revenue
Clean accrual-basis financials with a CFO or fractional CFO function
Demonstrated 10%+ year-over-year revenue and EBITDA growth

If you operate a mid-size psychiatry group and you're within 24 months of a sale, the highest-leverage work is professionalizing the management layer and lifting telepsychiatry mix. Both are directly multiple-additive.

Large Psychiatry Platform (11+ Providers, Multi-Site or Multi-State)

Typical multiple range: 8.0x – 12.0x+ adjusted EBITDA

Once a psychiatry practice crosses the platform threshold — generally 11+ credentialed providers, multi-site operations, a real C-suite, scaled telepsychiatry, and $4M+ of adjusted EBITDA — you're in private equity platform territory. These transactions price differently because the buyer isn't acquiring a practice; they're acquiring a platform they can build on.

Platform-level multiples are driven by:

Scarcity premium — there are very few true psychiatry platforms in any given region, and PE buyers compete hard for them
Roll-up potential — the buyer's underwriting includes the practices they'll bolt on later at lower multiples (multiple arbitrage)
Management strength — does the existing leadership team stay and run the platform?
Tech and data infrastructure — modern EHR, structured data, billing analytics, outcomes data
Defensible payer contracts — multi-state, multi-payer, with contracted rate visibility

Platforms with all of the above — and a credible 3-year growth plan — can command double-digit multiples. Platforms with operational gaps in any of those areas trade lower.

The Four Levers That Move You Inside the Multiple Range

Two psychiatry practices with the same EBITDA can transact at very different multiples. The difference almost always traces back to four levers — and three of the four are entirely within your control in the 12–24 months before launch.

Lever 1: Provider Concentration

The single biggest swing factor. A practice where the owning psychiatrist produces 75% of revenue is fundamentally different from one where the top provider produces 35%. Buyers explicitly price founder concentration into the multiple — sometimes one to two full turns lower — and often into the deal structure (longer earn-outs, larger equity rollover, extended seller transition).

The fix: Recruit and ramp at least one additional psychiatric clinician 18–24 months before sale. Document their independent panel. Shift selected high-acuity patients to associate providers.

Lever 2: Quality of Earnings Defensibility

Buyers don't pay full multiple on EBITDA they don't believe. If your add-back schedule isn't documented, your bookkeeping is cash-basis and unreconciled, or your owner-pay normalization is hand-waved, the buyer's QoE firm will strip it — and the offer will fall.

The fix: Move to accrual accounting at least 12 months pre-sale. Build a 36-month documented add-back schedule. Have a fractional CFO clean the books before launch.

Lever 3: Payer Mix and Contracted Rate Quality

Buyers pay different multiples for different payer profiles. Contracted commercial in-network revenue with strong rates is the sweet spot. Pure cash-pay is premium if it's durable. Heavy Medicaid concentration trades lower unless paired with scale or value-based contracts.

The fix: Audit your contracted rates by CPT code against AMA CPT market norms. Renegotiate the bottom-quartile contracts. Diversify away from any single payer above 35% of revenue.

Lever 4: Service-Line and Telepsychiatry Mix

Practices with credentialed, well-utilized TMS programs, Spravato (esketamine) REMS-certified workflows, and meaningful telepsychiatry penetration trade at higher multiples because each lifts contribution margin and creates differentiated patient retention.

The fix: If you have an underutilized TMS suite, get it to 70%+ utilization. If Spravato is clinically appropriate for your patient population, build the workflow. Move telepsychiatry mix toward 30–50% with multi-state licensure where demand supports it.

Download — 2026 Psychiatry Practice Market Update — Free

Current PE buyer activity, deal structures, and the platform-acquisition data shaping psychiatry M&A right now.

What's Driving Psychiatry Practice EBITDA Multiples in 2026

Three macro forces are shaping psychiatry multiples right now, and understanding them helps you time and structure your sale.

1. Continued PE-backed psychiatry platform consolidation.

Platforms like LifeStance, Mindpath Health, Talkiatry, and ARC Health continue to roll up psychiatry groups and solo practices to scale geographic reach, lift telepsychiatry penetration, and capture credentialed payer contracts. This sustained buyer demand is keeping multiples firm — particularly in the small-group and mid-size group bands.

2. Persistent psychiatrist supply-demand imbalance.

HRSA data continues to designate the majority of U.S. counties as Mental Health Professional Shortage Areas, and AAMC physician workforce projections show psychiatry as one of the most undersupplied specialties through 2034. Buyers underwrite this scarcity directly — a credentialed, productive psychiatrist is a strategically valuable asset, and that scarcity supports multiples.

3. Telepsychiatry as a structural value driver.

Sustained post-2020 telepsychiatry adoption, combined with DEA controlled substance prescribing flexibilities and multi-state licensure pathways, has turned telepsychiatry from a service line into a multiple driver. Practices that have built durable telepsychiatry infrastructure are commanding meaningfully higher multiples than equivalent in-person-only practices.

The forces pulling against higher multiples in some deals: payer rate pressure on certain commercial contracts, reimbursement uncertainty for some Medicaid lines, and continued workforce cost inflation for psychiatric clinicians. Buyers are pricing these in — which is why clean documentation and demonstrated growth are more important than ever.

Multi-Provider Premium: Why Two Psychiatrists Are Worth More Than Twice One

The data point that surprises most solo psychiatrists: adding one additional psychiatrist to a solo practice doesn't just double the EBITDA — it can lift the multiple by one to two turns at the same time, because the practice has crossed the structural threshold from "personal services business" to "small clinical organization."

The math compounds. If a solo psychiatry practice with $400K of adjusted EBITDA is trading at 3.5x ($1.4M enterprise value), and adding one productive psychiatrist lifts adjusted EBITDA to $700K and lifts the multiple to 5.5x, the new enterprise value is $3.85M. That's a $2.45M increase at closing for a single recruiting decision made 18–24 months before going to market.

This is why the work in the 12–24 months before launch is, dollar for dollar, the highest-ROI period in any psychiatry owner's career.

LEARN MORE —What Buyers Look For When Evaluating Your Psychiatry Practice

Exactly what diligence focuses on when buyers evaluate your practice.

LEARN MORE — Why Private Equity Firms Buy Psychiatry Practices

How PE buyers underwrite multiple expansion in psychiatry.

How Olympic M&A Positions Psychiatry Practices to Maximize Multiple

When we run a psychiatry practice sale, we don't just market the business — we market the right buyer set in a structured competitive process designed to push the multiple to its defensible ceiling.

Our process for psychiatry practice sales includes:

Bottom-up adjusted EBITDA build with documented add-backs that survive QoE
Buyer universe mapping — institutional psychiatry platforms, regional consolidators, strategic acquirers, and qualified individual buyers
Confidential, structured outreach under NDA to the highest-fit buyers
Multiple-round bidding designed to surface the true ceiling, not the first acceptable offer
Deal-structure negotiation beyond the multiple — earn-outs, equity rollover, employment terms, real estate, retention pools
Closing execution — managing legal, QoE, regulatory, and licensure workstreams to a clean close

The headline multiple is only one piece of what a real advisor delivers. Total economics — cash at close, rollover value, earn-out terms, employment compensation, and tax-efficient structuring — is what determines the actual value you walk away with.

LEARN MORE — How to Sell a Psychiatry Practice — The Complete Guide

The full process walkthrough from preparation to close.

Frequently Asked Questions About Psychiatry Practice EBITDA Multiples

What is the average EBITDA multiple for a psychiatry practice?

There is no single "average" — multiples range from roughly 2.5x for the smallest solo practices with retiring owners and limited differentiation, to 12x+ for institutional psychiatry platforms with scaled telepsychiatry, multi-state operations, and strong management. Most psychiatry practice transactions cluster in the 4x–8x range based on size, provider depth, and quality of earnings.

How do I know my psychiatry practice's adjusted EBITDA?

Adjusted EBITDA starts with your reported earnings and adds back owner compensation above market, personal expenses run through the practice, and one-time costs — while subtracting the cost of replacing the selling psychiatrist's clinical work at market rate. This is exactly the kind of analysis we deliver in a written valuation. Read more in our Psychiatry Practice Valuation guide.

Why does a multi-provider psychiatry group sell at a higher multiple than a solo?

Buyers pay higher multiples for practices with reduced founder dependency. A multi-provider group has provider redundancy, demonstrable independent panel growth across clinicians, and a management layer that doesn't disappear when the founder leaves. That structural difference often lifts the multiple by 1–2 turns on the same dollar of EBITDA.

Does telepsychiatry really increase my multiple?

Yes. Practices with 30–50% telepsychiatry mix, durable patient retention, and multi-state licensure consistently command higher multiples than equivalent in-person-only practices because telepsychiatry expands the addressable market, lifts provider productivity, and creates scalable growth without proportional real estate cost.

How does payer mix affect my multiple?

Buyers price payer mix into the multiple. Strong contracted commercial in-network rates with diversified payers is the sweet spot. Durable cash-pay or out-of-network revenue can command premium multiples if the durability is demonstrable. Heavy Medicaid concentration without scale or value-based contracts typically prices lower. Single-payer concentration above 35% creates a discount.

What's the fastest way to lift my multiple before going to market?

The four highest-impact levers, in order: (1) recruit and ramp at least one additional psychiatric clinician to reduce founder concentration, (2) clean and document financials to survive QoE, (3) renegotiate underpriced payer contracts, and (4) lift telepsychiatry penetration and underutilized service lines like TMS or Spravato.

Should I wait for multiples to expand before selling?

The honest answer is that no advisor can time the market for you. What you can control is the position your practice is in when you do go to market. A practice that goes to market in 18 months at the top of its multiple range will almost always outperform a practice that rushes to market today at the bottom of its range. The question isn't "are multiples expanding?" — it's "is my practice ready to capture the top of its range?"

About Tony Siebel

Founder & Managing Director, Olympic M&A

Tony Siebel is the Founder & Managing Director of Olympic M&A and one of the country's most active healthcare practice M&A advisors. Named to the Top 50 M&A Advisors of 2025, Tony has personally led more than $70M in completed healthcare M&A transactions and authored 60+ articles on healthcare practice valuation, sale readiness, and structured competitive sale processes.

Tony's expertise in the psychiatry and TMS industry is unparalleled. He understood our practice, our patients, and our growth story — and ran a process that delivered a result well above what other advisors had quoted us. He is the advisor I recommend to any psychiatrist thinking about a sale.

— Brian E., MD · Psychiatry Practice Owner

Tony advises psychiatry practice owners across the U.S. on practice valuation, sale preparation, buyer selection, and deal execution — always with the same goal: a confidential, competitive process that delivers the best possible outcome for the owner and the practice.

olympicma.com | tonys@olympicma.com | 502.360.8320

Join the Webinar — The Truth About Selling Your Psychiatry Practice in 2026–2027

A live, confidential webinar for psychiatry practice owners exploring what comes next. Insider perspective on valuation, buyer types, and how to protect what you've built. No pressure, no prep needed.